China’s leading vaccine producer CanSino Biologics obtained the national drug regulator’s approval on Monday to start clinical trials of its latest recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) in inhalation form.
The Global Times learned that the vaccine, which was developed in cooperation with the Institute of Military Medicine under the Academy of Military Sciences, is no different in terms of virus species, cell banks, production technology or preparation formula from the company’s single-dose Ad5-nCoV COVID-19 vaccine, which is already in use – it just has an additional atomization inhalation device.
The inhaled vaccine can stimulate an immune response in the mucous membranes of a person’s respiratory tract. This version is less painful and more accessible, especially for children andvulnerable people, experts said. Source: Clinical trials approved for CanSino’s inhaled COVID-19 vaccine – Global Times